Workflow
科创板投资
icon
Search documents
兴业上证科创板综合价格交易型开放式指数证券投资基金联接基金基金份额发售公告
登录新浪财经APP 搜索【信披】查看更多考评等级 7、本基金自基金份额发售之日起3个月内,在基金募集份额总额不少于2亿份,基金募集金额不少于2亿 元人民币且基金认购人数不少于200人的条件下,基金募集期届满或基金管理人依据法律法规及招募说 明书可以决定停止基金发售,并在10日内聘请法定验资机构验资,自收到验资报告之日起10日内,向中 国证监会办理基金备案手续。 基金管理人: 兴业基金管理有限公司 基金托管人: 中国邮政储蓄银行股份有限公司 重要提示 1、兴业上证科创板综合价格交易型开放式指数证券投资基金联接基金(以下简称"本基金")的募集已 获中国证监会2025年4月7日证监许可[2025]707 号文准予募集注册。中国证监会对本基金募集的注册并 不代表其对本基金的投资价值和市场前景作出实质性判断或保证,也不表明投资于本基金没有风险。 2、本基金是契约型开放式证券投资基金。 本基金为ETF联接基金,目标ETF为股票型基金,其预期收益及预期风险水平高于混合型基金、债券型 基金与货币市场基金。本基金主要通过投资于目标ETF跟踪标的指数表现,具有与标的指数以及标的指 数所代表的证券市场相似的风险收益特征。 3、本基 ...
科创板投资再推利器 建信上证科创板200ETF正式发行
Zhong Guo Jing Ji Wang· 2025-08-20 08:58
Group 1 - The core viewpoint is that Jianxin Fund is focusing on opportunities in the Sci-Tech Innovation Board, launching multiple ETFs to cater to diverse investment needs in this sector [1][2] - Since its establishment over six years ago, the Sci-Tech Innovation Board has evolved from a "testing ground" to a "new highland" for innovative industries, with small-cap companies becoming a significant part of the board [1] - As of August 19, there are 364 listed companies on the Sci-Tech Innovation Board with a total market capitalization below 10 billion yuan, accounting for 62% of all listed companies, and these companies have a combined R&D investment of 36 billion yuan for 2024 [1] Group 2 - The Jianxin SSE Sci-Tech Innovation Board 200 ETF will be managed by experienced fund manager Gong Jiajia, who has 12 years of experience in the securities industry and has managed six ETF products [2] - The Jianxin SSE Sci-Tech Innovation Board 200 ETF is part of a broader strategy to provide three flagship index products for investors, addressing various investment demands in the Sci-Tech sector [2] - The Jianxin SSE Sci-Tech Innovation Board 200 ETF focuses on small-cap assets, offering stronger yield elasticity and complementing the other two ETFs that cover the overall market and focus on high-quality, low-valuation companies [2]
易方达上证科创板综合增强策略交易型开放式指数证券投资基金基金份额发售公告
Group 1 - The fund is named "E Fund Shanghai Stock Exchange Science and Technology Innovation Board Comprehensive Enhanced Strategy ETF" and is a type of open-ended index fund [23] - The fund will be available for subscription from August 18 to August 22, 2025, with both online and offline cash subscription options [2][23] - The maximum fundraising scale for the fund is set at 2 billion RMB, excluding interest and subscription fees [5][23] Group 2 - Investors must have a Shanghai Stock Exchange A-share account or a securities investment fund account to subscribe to the fund [3][44] - The subscription fee for the fund will not exceed 0.80% of the subscribed amount [4][28] - The fund's investment objective is to pursue returns that exceed the performance benchmark while controlling the average tracking deviation and annualized tracking error [24][25] Group 3 - The fund's underlying index is the Shanghai Stock Exchange Science and Technology Innovation Board Comprehensive Index, which includes stocks listed on the Science and Technology Innovation Board [12][13] - The fund will be managed by E Fund Management Co., Ltd., with Ping An Bank as the custodian [1][64] - The fund's shares will be issued at an initial value of 1 RMB per share [23]
上交所ETF“科创引领”华安基金首场专场活动成功举办|共探科创投资新方向,分享ETF配置新思路
Xin Lang Ji Jin· 2025-06-13 02:25
Group 1 - The event focused on investment opportunities in the Sci-Tech Innovation Board and ETF allocation strategies, aiming to provide professional insights for investors [1][2] - The Sci-Tech Innovation Board has achieved significant results in institutional innovation and market ecology optimization over the past six years, providing strong support for technology innovation enterprises [2][3] - The event attracted numerous institutional and individual investors, fostering a lively atmosphere for exchange [2][3] Group 2 - The Shanghai Stock Exchange presented a comprehensive overview of the development of the Sci-Tech Innovation Board and the latest trends in the ETF market, highlighting over 20 newly released indices that support key areas of technology innovation [3] - Huazhang Fund's Chief Index Investment Officer discussed the unique investment value of the Sci-Tech Innovation Board in the "hard technology" sector and shared strategies for capturing investment opportunities through related ETF products [3] - Southwest Securities' Chief Analyst emphasized the core role of ETFs in optimizing asset allocation, providing practical investment strategies tailored to different risk preferences [6] Group 3 - The event was part of the Shanghai Stock Exchange's "Sci-Tech Leadership" theme month, showcasing the collaboration of the three institutions to enhance investor understanding of the Sci-Tech Innovation Board and Shanghai ETFs [6][8] - Huazhang Fund committed to enhancing investor services and providing efficient index investment tools, aligning with regulatory initiatives for high-quality development in public funds [8]
港股创新药ETF霸榜跨境产品,17只年内收益超40%,这两类主题ETF占私募配置过半
Hua Xia Shi Bao· 2025-05-30 13:45
Core Viewpoint - The Hong Kong innovative pharmaceutical sector has gained significant traction in the capital market this year, with a notable performance of related ETFs, indicating strong investor interest and potential growth in the industry [3][5]. Group 1: Performance of ETFs - As of May 30, 2023, the top 17 cross-border ETFs in terms of returns are all related to Hong Kong pharmaceuticals, with annual returns exceeding 40% [3][5]. - Specific ETFs such as the Huatai-PB Hang Seng Innovative Drug ETF and the GF CSI Hong Kong Innovative Drug ETF have reported returns of 43.36% and 42.09% respectively [5]. - The total net inflow of funds into these ETFs has been substantial, with the Huatai-PB ETF seeing an increase of 19.78 million shares [5]. Group 2: Private Equity Interest - Private equity firms have shown a strong preference for newly listed ETFs, particularly in the sci-tech sector, with 104 private equity products appearing in the top ten holdings of 97 newly listed ETFs, holding a total of 1.783 billion shares [3][8]. - The sci-tech ETFs have attracted 32.02% of the total shares held by private equity, indicating a robust interest in high-growth potential sectors [8]. Group 3: Future Outlook for Innovative Pharmaceuticals - Industry experts express optimism regarding the investment potential in innovative pharmaceuticals, citing favorable policies and market conditions as catalysts for growth [4][6]. - The ongoing development of innovative drugs is supported by government initiatives, which aim to streamline approval processes and enhance market access [7][8]. - The increasing demand for innovative drugs is driven by an aging population and heightened health awareness, suggesting a sustainable growth trajectory for the sector [7][8]. Group 4: Free Cash Flow ETFs - Newly listed free cash flow ETFs have emerged as a popular choice among private equity investors, with 16 such ETFs collectively holding 350 million shares [10][12]. - These ETFs focus on companies with strong cash flow, reflecting their true profitability and financial health, which is increasingly appealing in the current market environment [11][12]. - The demand for stable, high-quality investment options has led to a growing interest in free cash flow ETFs, which offer both cash returns and growth potential [12].